FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trialResearch in context

FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trialResearch in context

Summary: Background: Currently, assessment of candidate pharmacotherapies in patients with non-alcoholic steatohepatitis (NASH) involves invasive liver biopsy. Non-invasive scores, such as the FibroScan-aspartate aminotransferase (FAST) score, are used to identify candidates for therapy, but their...

書誌詳細
主要な著者:	Vincent Wai-Sun Wong, Quentin M. Anstee, Louise M. Nitze, Anja Geerts, Jacob George, Victor Nolasco, Mette S. Kjær, Steen Ladelund, Philip N. Newsome, Vlad Ratziu
フォーマット:	論文
言語:	English
出版事項:	Elsevier 2023-12-01
シリーズ:	EClinicalMedicine
主題:	Biomarkers Clinical trial Non-alcoholic steatohepatitis NASH Semaglutide
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S258953702300487X

類似資料

Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration
著者:: Evgenia Koureta, 等
出版事項: (2024-02-01)

Semaglutide improves metabolic dysfunction‐associated steatohepatitis: A 10‐year retrospective study
著者:: Parth Shah, 等
出版事項: (2024-02-01)

Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria
著者:: Jae Seung Lee, 等
出版事項: (2022-04-01)

Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
著者:: Magdalena Mazurek, 等
出版事項: (2023-02-01)

The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children
著者:: Alexander Chaidez, 等
出版事項: (2022-11-01)

Pathohistological characteristics of steatohepatitis on needle biopsy sample from 100 patients
著者:: Milićević Anđela, 等
出版事項: (2019-01-01)

Changes in histological criteria lead to different prevalences of nonalcoholic steatohepatitis in severe obesity
著者:: Cacilda Pedrosa de Oliveira, 等
出版事項: (2007-10-01)

Adherence and treatment discontinuation of oral semaglutide and once‐weekly semaglutide injection at 12 month follow‐up: Japanese real‐world data
著者:: Takeshi Horii, 等
出版事項: (2024-11-01)

Semaglutide for the treatment of obesity
著者:: Rafał Oleszczuk, 等
出版事項: (2022-01-01)

Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity
著者:: Joseph L. Jilek, 等
出版事項: (2021-12-01)

The efficacy of multi‐disciplinary lifestyle modifications in Taiwanese nonalcoholic steatohepatitis patients
著者:: Ming‐Lun Yeh, 等
出版事項: (2024-06-01)

Angiogenic effects of leptin in patients with nonalcoholic steatohepatitis
著者:: Gaafar Nagah, 等
出版事項: (2005-01-01)

Double Trouble: How Microbiome Dysbiosis and Mitochondrial Dysfunction Drive Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
著者:: Wesam Bahitham, 等
出版事項: (2024-02-01)

The craze with semaglutide
著者:: Ruby Dhar, 等
出版事項: (2024-06-01)

Dose-dependent erythema nodosum after initiation of semaglutide
著者:: Jeffrey Sobieraj, MD, 等
出版事項: (2024-05-01)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
著者:: Han Na Jung, 等
出版事項: (2022-03-01)

Validation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials
著者:: Hanna Pulaski, 等
出版事項: (2024-09-01)

Spotlight on the Mechanism of Action of Semaglutide
著者:: Ilias Papakonstantinou, 等
出版事項: (2024-12-01)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
著者:: Takeshi Hatanaka, 等
出版事項: (2021-10-01)

Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis
著者:: Wim Verlinden, 等
出版事項: (2020-11-01)

Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis
著者:: Adam Minich, 等
出版事項: (2022-08-01)

Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations
著者:: Camille Pichon, 等
出版事項: (2022-11-01)

Diagnostic accuracy of FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis in patients with chronic hepatitis B with metabolic dysfunction-associated fatty liver disease
著者:: Youwen Tan, 等
出版事項: (2024-12-01)

Semaglutide in the Treatment of Diabetes and Associated Obesity
著者:: Rafal Makuch, 等
出版事項: (2024-06-01)

A real‐world disproportionality analysis of semaglutide: Post‐marketing pharmacovigilance data
著者:: Yikuan Du, 等
出版事項: (2024-10-01)

The Synthesis of SNAC Phenolate Salts and the Effect on Oral Bioavailability of Semaglutide
著者:: Tovi Shapira-Furman, 等
出版事項: (2024-08-01)

A New Hope for the Patients of Non‐Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use
著者:: Abdul Haseeb Hasan, 等
出版事項: (2025-01-01)

Contractile Effects of Semaglutide in the Human Atrium
著者:: Joachim Neumann, 等
出版事項: (2024-08-01)

Elastographic liver evaluation of Katukyadi churna in the management of Non-Alcoholic Steatohepatitis (NASH) – A single arm clinical trial.
著者:: Shruti Tarapure, 等
出版事項: (2021-01-01)

Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide
著者:: Peter Bracha, 等
出版事項: (2024-12-01)

Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice
著者:: Yang Y, 等
出版事項: (2024-03-01)

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
著者:: Shu Niu, 等
出版事項: (2022-12-01)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
著者:: Takahiro Iijima, 等
出版事項: (2023-06-01)

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
著者:: Mansoor Husain, 等
出版事項: (2020-09-01)

Beneficial effects of ginkgetin on improving nonalcoholic steatohepatitis characterized by bulk and single-cell RNA sequencing analysis
著者:: Chaoyang Wang, 等
出版事項: (2023-10-01)

Nonobese mice with nonalcoholic steatohepatitis fed on a choline‐deficient, l‐amino acid‐defined, high‐fat diet exhibit alterations in signaling pathways
著者:: Noriko Suzuki‐Kemuriyama, 等
出版事項: (2021-11-01)

The Discovery and Development of Liraglutide and Semaglutide
著者:: Lotte Bjerre Knudsen, 等
出版事項: (2019-04-01)

Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study
著者:: Louis Talay, 等
出版事項: (2024-10-01)

Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
著者:: Xiaoyi Chen, 等
出版事項: (2023-03-01)

Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western DietSummary
著者:: Souradipta Ganguly, 等
出版事項: (2021-01-01)